Tasia-Leigh Deleon | Manager of Cosmetovigilance
CHANEL

Tasia-Leigh Deleon, Manager of Cosmetovigilance, CHANEL

Tasia-Leigh Deleon is the manager of Cosmetovigilance for CHANEL’s US division. With nearly two decades of experience in healthcare, Tasia has built a dynamic career that bridges clinical practice, pharmaceutical expertise, and global business operations. She began her professional journey as a pediatric nurse, where her compassion and dedication shaped the early years of her career. Eager to expand her horizons, Tasia transitioned into the pharmaceutical industry, quickly rising to become the lead aggregate report writer. In this role, she demonstrated a keen eye for detail and a deep understanding of regulatory requirements. Her leadership was instrumental when her company went global, as she project-managed and implemented the Periodic Safety Update Report (PSUR) process—ensuring compliance and streamlined reporting across international markets. Three years ago, Tasia embraced a new challenge by joining CHANEL. Her blend of clinical knowledge, regulatory expertise, and project management skills have made her a valuable asset to the team, continuing to drive innovation and excellence in every endeavor. As part of CHANEL’s Cosmetovigilance Team, she is responsible for managing projects that support the safe and effective use of CHANEL’s products, while upholding the highest standards of regulatory compliance.

Appearances:



Pre-Conference Day - World Drug Safety Congress USA 2025 @ 16:00

THE MODERN MAKEOVER: A deeper dive into MoCRA's new requirements

Day 1 - World Drug Safety Congress Americas 2025 @ 15:20

Panel: Navigating Patient Safety: A Comparative Look Across Pharma, Devices, Cosmetics, and Combination Products

A panel on "Navigating Patient Safety: A Comparative Look Across Pharma, Devices, Cosmetics, and Combination Products" would explore the unique and overlapping safety challenges within each sector. Experts would discuss regulatory frameworks, risk management strategies, and post-market surveillance practices tailored to the specific nature of each product type. The conversation would highlight how innovation, globalization, and evolving consumer expectations are reshaping safety protocols. Ultimately, the session would aim to foster a more integrated approach to patient safety across the life sciences spectrum.

last published: 06/Nov/25 15:05 GMT

back to speakers

Get Involved At Drug Safety Congress Americas

 

CONNECT WITH US

 

To Sponsor

Semen Sen
semen.sen@terrapinn.com
t/ + 646-619-1793

Annabelle Pearson
Annabelle.Pearson@terrapinn.com

 

To Speak

Kaylee Nguyen
kaylee.nguyen@terrapinn.com

 

Marketing & Press

Karolina Bzikot
karolina.bzikot@terrapinn.com